13/120
0.5 / 5 stars
All 120 Win/Lose results shown below
SKYE Roast Me summary
Skye Bioscience, Inc. (SKYE). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 0 wins, 12 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseSKYE / S&P 12.68% / 15.20% |
LoseSKYE / S&P SKYE unavailable / 15.00% |
LoseSKYE / S&P SKYE unavailable / 50.40% |
| 2026-Q10/3 |
LoseSKYE / S&P -18.00% / -4.33% |
LoseSKYE / S&P SKYE unavailable / 11.30% |
LoseSKYE / S&P SKYE unavailable / 27.70% |
| 2025-Q40/3 |
LoseSKYE / S&P -80.92% / 2.65% |
LoseSKYE / S&P SKYE unavailable / 9.00% |
LoseSKYE / S&P SKYE unavailable / 13.40% |
| 2025-Q30/3 |
LoseSKYE / S&P -5.98% / 8.12% |
LoseSKYE / S&P SKYE unavailable / 4.61% |
LoseSKYE / S&P -343.40% / 13.45% |
| 2025-Q21/3 |
WinSKYE / S&P 162.89% / 10.94% |
LoseSKYE / S&P SKYE unavailable / 4.83% |
LoseSKYE / S&P SKYE unavailable / 10.63% |
| 2025-Q10/3 |
LoseSKYE / S&P -43.82% / -4.27% |
LoseSKYE / S&P SKYE unavailable / 4.98% |
LoseSKYE / S&P SKYE unavailable / 10.57% |
| 2024-Q40/3 |
LoseSKYE / S&P -27.62% / 2.41% |
LoseSKYE / S&P SKYE unavailable / 5.25% |
LoseSKYE / S&P SKYE unavailable / 6.15% |
| 2024-Q30/3 |
LoseSKYE / S&P -51.19% / 5.89% |
LoseSKYE / S&P SKYE unavailable / 5.89% |
LoseSKYE / S&P SKYE unavailable / 6.11% |
| 2024-Q20/3 |
LoseSKYE / S&P -48.79% / 4.28% |
LoseSKYE / S&P SKYE unavailable / 5.38% |
LoseSKYE / S&P SKYE unavailable / 5.12% |
| 2024-Q11/3 |
WinSKYE / S&P 475.00% / 10.56% |
LoseSKYE / S&P SKYE unavailable / 5.71% |
LoseSKYE / S&P SKYE unavailable / 5.59% |
| 2023-Q40/3 |
LoseSKYE / S&P -33.50% / 11.69% |
LoseSKYE / S&P SKYE unavailable / 6.81% |
LoseSKYE / S&P SKYE unavailable / 7.78% |
| 2023-Q30/3 |
LoseSKYE / S&P -22.10% / -3.27% |
LoseSKYE / S&P SKYE unavailable / 7.52% |
LoseSKYE / S&P SKYE unavailable / -5.03% |
| 2023-Q21/3 |
WinSKYE / S&P 23.53% / 8.74% |
LoseSKYE / S&P SKYE unavailable / 9.50% |
LoseSKYE / S&P SKYE unavailable / -8.57% |
| 2023-Q10/3 |
LoseSKYE / S&P 6.25% / 7.50% |
LoseSKYE / S&P SKYE unavailable / 10.77% |
LoseSKYE / S&P SKYE unavailable / -15.69% |
| 2022-Q40/3 |
LoseSKYE / S&P -38.46% / 7.56% |
LoseSKYE / S&P SKYE unavailable / 11.88% |
LoseSKYE / S&P SKYE unavailable / -17.99% |
| 2022-Q30/3 |
LoseSKYE / S&P -25.71% / -4.88% |
LoseSKYE / S&P SKYE unavailable / 13.47% |
LoseSKYE / S&P SKYE unavailable / -1.41% |
| 2022-Q21/3 |
WinSKYE / S&P -7.89% / -16.10% |
LoseSKYE / S&P SKYE unavailable / 13.71% |
LoseSKYE / S&P SKYE unavailable / 11.04% |
| 2022-Q10/3 |
LoseSKYE / S&P -26.92% / -4.60% |
LoseSKYE / S&P SKYE unavailable / 15.97% |
LoseSKYE / S&P SKYE unavailable / 42.23% |
| 2021-Q40/3 |
LoseSKYE / S&P -50.48% / 11.03% |
LoseSKYE / S&P SKYE unavailable / 15.00% |
LoseSKYE / S&P SKYE unavailable / 96.40% |
| 2021-Q30/3 |
LoseSKYE / S&P -34.78% / 0.58% |
LoseSKYE / S&P SKYE unavailable / 10.77% |
LoseSKYE / S&P SKYE unavailable / 69.42% |
| 2021-Q21/3 |
WinSKYE / S&P 35.29% / 8.55% |
LoseSKYE / S&P SKYE unavailable / 6.58% |
LoseSKYE / S&P SKYE unavailable / 51.81% |
| 2021-Q11/3 |
WinSKYE / S&P 197.50% / 6.17% |
LoseSKYE / S&P SKYE unavailable / -1.06% |
LoseSKYE / S&P -400.00% / 7.39% |
| 2020-Q40/3 |
LoseSKYE / S&P -4.76% / 12.15% |
LoseSKYE / S&P SKYE unavailable / -3.72% |
LoseSKYE / S&P SKYE unavailable / -33.42% |
| 2020-Q30/3 |
LoseSKYE / S&P -73.25% / 8.93% |
LoseSKYE / S&P SKYE unavailable / -2.04% |
LoseSKYE / S&P SKYE unavailable / -27.10% |
| 2020-Q21/3 |
WinSKYE / S&P 109.33% / 20.54% |
LoseSKYE / S&P SKYE unavailable / -0.46% |
LoseSKYE / S&P SKYE unavailable / -27.11% |
| 2020-Q10/3 |
LoseSKYE / S&P -42.75% / -19.60% |
LoseSKYE / S&P SKYE unavailable / 3.47% |
LoseSKYE / S&P SKYE unavailable / -14.75% |
| 2019-Q40/3 |
LoseSKYE / S&P -64.59% / 9.07% |
LoseSKYE / S&P SKYE unavailable / 5.36% |
LoseSKYE / S&P SKYE unavailable / 2.99% |
| 2019-Q31/3 |
WinSKYE / S&P 27.59% / 1.70% |
LoseSKYE / S&P SKYE unavailable / 5.02% |
LoseSKYE / S&P SKYE unavailable / 0.21% |
| 2019-Q20/3 |
LoseSKYE / S&P -57.97% / 4.30% |
LoseSKYE / S&P SKYE unavailable / 6.64% |
LoseSKYE / S&P SKYE unavailable / 8.65% |
| 2019-Q11/3 |
WinSKYE / S&P 72.50% / 13.65% |
LoseSKYE / S&P SKYE unavailable / 8.12% |
LoseSKYE / S&P SKYE unavailable / 14.29% |
| 2018-Q41/3 |
WinSKYE / S&P 33.33% / -13.52% |
LoseSKYE / S&P SKYE unavailable / 9.05% |
LoseSKYE / S&P SKYE unavailable / 18.23% |
| 2018-Q31/3 |
WinSKYE / S&P 8.70% / 7.71% |
LoseSKYE / S&P SKYE unavailable / 10.21% |
LoseSKYE / S&P SKYE unavailable / 19.06% |
| 2018-Q21/3 |
WinSKYE / S&P 15.97% / 3.43% |
LoseSKYE / S&P SKYE unavailable / 9.03% |
LoseSKYE / S&P SKYE unavailable / 14.46% |
| 2018-Q11/3 |
WinSKYE / S&P 56.58% / -0.76% |
LoseSKYE / S&P SKYE unavailable / 7.68% |
LoseSKYE / S&P SKYE unavailable / 12.46% |
| 2017-Q40/3 |
LoseSKYE / S&P -41.31% / 6.64% |
LoseSKYE / S&P SKYE unavailable / 7.03% |
LoseSKYE / S&P SKYE unavailable / 13.82% |
| 2017-Q30/3 |
LoseSKYE / S&P -16.45% / 4.48% |
LoseSKYE / S&P SKYE unavailable / 5.68% |
LoseSKYE / S&P SKYE unavailable / 17.57% |
| 2017-Q20/3 |
LoseSKYE / S&P 0.00% / 3.09% |
LoseSKYE / S&P SKYE unavailable / 4.83% |
LoseSKYE / S&P SKYE unavailable / 17.74% |
| 2017-Q10/3 |
LoseSKYE / S&P 2.65% / 6.07% |
LoseSKYE / S&P SKYE unavailable / 3.67% |
LoseSKYE / S&P SKYE unavailable / 13.32% |
| 2016-Q40/3 |
LoseSKYE / S&P -35.74% / 3.82% |
LoseSKYE / S&P SKYE unavailable / 2.09% |
LoseSKYE / S&P SKYE unavailable / 7.05% |
| 2016-Q30/3 |
LoseSKYE / S&P -4.47% / 3.85% |
LoseSKYE / S&P SKYE unavailable / 0.20% |
LoseSKYE / S&P SKYE unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | SKYE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -49.67% | 20.78% |
| Annualized return | -49.67% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | SKYE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.82% | 83.14% |
| Annualized return | -44.68% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | SKYE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.74% | 319.30% |
| Annualized return | -35.44% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |